Læknablaðið : fylgirit - 01.05.1978, Page 76

Læknablaðið : fylgirit - 01.05.1978, Page 76
O. Strandberg, M. D. , Department of Rheuma- tology, Danderyd Hospital, Sweden. Elisabeth Wijnbladh, M. D., Saltsjöbaden Hospital, Stockholm, Sweden. FerastralW, Astra 2152, is a sterile solution of a complex of iron and a sorbitol glueonic acid polymer, containing 50 mg Fe+++/ml. The preparation can be used in relatively large doses (500 mg) with 3-7 day's interval (Andersson, Grafford, 1975, Swedberg, 1975). In this study, 15 patients with moderate anaemia and subnormal MCHC were treated with Ferastral. In all the patients inflammatory processes, in most cases active rheumatoid arthritis, was the underlying cause. Diagnostic criteria according to American Rheumatism Association were fulfilled. Concomitant therapy consisted of usual anti-inflammatory drugs, such as salicylates, indomethacin, naproxene, and in some cases very low doses of penicillamine. Local therapy with corticosteroids íh very small doses was also used in some cases. The corticosteroid doses thus given were too small to affect the haematopoetic system (Strandberg, 1966). The total doses in mg were estimated by multiplying the haemoglobin deficit in mg/100 ml. by 225 (Brown & Moore, 1956) plus 500 mg for the iron stores. Another method to estimate the expected total iron dose to be given is to multiply desired haematocrit rise by 100 (Mc Curdy, 1970). The total doses given ranged between 1250 mg and 3500 mg, the major part of the patients receiving about 2000 mg. It was given in single doses of 500 mg with an interval of about one week. 3 patients received lower single doses of 250 and 100 mg. Laboratory methods: Haemoglobin was determined by the cyan methaemoglobin method. Erythrocytes were counted in a Coulter counter, and the packed cell volume was determined after 5 minutes centrifuga- tion in a haematocrit centrifuge. Serum iron concentration was determined according to Heil- meyer and Plötner (1937) and UIBC according to Cartwright and Wintrobe (1949). Agarose gel electrophoresis according to H Johansson (1972). Serum albumin concentration according to Doumas (1971) and haptoglobin (Tai-ukoski, 1966) were determined with chemical methods. Alpha-1- FERESTRAL IN THE TREATMENT OF PATIENTS WITH INF LAMMATORY ANAEMIA trypsine, orosomucoid, C'3, C’4 complement fractions, immune globulins G, A, M and trans- ferrin were determined with electro immune assay (Laurell 1972). R esults : The haemoglobin data during the observation period and at least 6 weeks after the start of the trial - the majority of the patients were followed for 8-12 weeks - have been tabulated in every detail, but are not discussed in detail. The statistical treatment of the pertinent data are tabulated (table 2). Every patient served as in its own control and the t-value for the differences between the means for 4 and 8 weeks and the means at the beginning of treatment were calculated. The haemoglobin concentration rose after 8 weeks significantly (P < 0.001) from 109.2 to 122.6 g/1. Although the means for the packed cell volumes displayed a rising tendency, the differences 4 and 8 weeks after the last injection were not statisti- cally significant. The erythrocyte count rose from 4.06 to 4.24 x 106/mm3 (0.1 > P > 0.01). The MCHC means rose from 317 to 334 g/1 (0.01> P> 0.001) at 8 weeks and after 4 weeks from 317 to 324 (0.1 > P > 0.01). The mean serum iron concentration beginning with 40.4 mg/100 ml rose to 68.9 (0. 01 > P> 0.001). The UIBC decreased from 279.3 to 171.8 mg/ml (0.01> P> 0.001). In the small series of trans- ferrin determinations, the same tendency as for UBBC was obtained. The mean decreased from 1.95 to 1.40 g/1 after 8 weeks (0.1 > P> 0. 01). No changes were obtained in the agarose electrophoresis pattern, nor in the serum protein components. Only C’4 showed slightly rising tendency, from 0.16 to 0.20 g/1 (0.1> P > 0. 01). Liver and kidney tests were followed during the test period, without changes (Add. No. 8). Side effects: A brownish discolouration at the injection site was observed in 8/17 patients receiving this iron 74
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19
Page 20
Page 21
Page 22
Page 23
Page 24
Page 25
Page 26
Page 27
Page 28
Page 29
Page 30
Page 31
Page 32
Page 33
Page 34
Page 35
Page 36
Page 37
Page 38
Page 39
Page 40
Page 41
Page 42
Page 43
Page 44
Page 45
Page 46
Page 47
Page 48
Page 49
Page 50
Page 51
Page 52
Page 53
Page 54
Page 55
Page 56
Page 57
Page 58
Page 59
Page 60
Page 61
Page 62
Page 63
Page 64
Page 65
Page 66
Page 67
Page 68
Page 69
Page 70
Page 71
Page 72
Page 73
Page 74
Page 75
Page 76
Page 77
Page 78
Page 79
Page 80
Page 81
Page 82
Page 83
Page 84
Page 85
Page 86
Page 87
Page 88
Page 89
Page 90
Page 91
Page 92
Page 93
Page 94
Page 95
Page 96
Page 97
Page 98
Page 99
Page 100
Page 101
Page 102
Page 103
Page 104
Page 105
Page 106
Page 107
Page 108
Page 109
Page 110
Page 111
Page 112
Page 113
Page 114
Page 115
Page 116
Page 117
Page 118
Page 119
Page 120
Page 121
Page 122
Page 123
Page 124
Page 125
Page 126
Page 127
Page 128
Page 129
Page 130
Page 131
Page 132
Page 133
Page 134
Page 135
Page 136
Page 137
Page 138
Page 139
Page 140
Page 141
Page 142
Page 143
Page 144
Page 145
Page 146
Page 147
Page 148
Page 149
Page 150
Page 151
Page 152
Page 153
Page 154
Page 155
Page 156
Page 157
Page 158

x

Læknablaðið : fylgirit

Direct Links

If you want to link to this newspaper/magazine, please use these links:

Link to this newspaper/magazine: Læknablaðið : fylgirit
https://timarit.is/publication/991

Link to this issue:

Link to this page:

Link to this article:

Please do not link directly to images or PDFs on Timarit.is as such URLs may change without warning. Please use the URLs provided above for linking to the website.